ATN blood biomarkers are related to digital cognitive assessment in type 1 diabetes.

IF 4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-10-23 eCollection Date: 2024-10-01 DOI:10.1002/dad2.70029

Luciana Mascarenhas Fonseca, Michal Schnaider Beeri, Zoë W Hawks, Lanee Jung, Michael Cleveland, Nikki Delgado, Jane Bulger, Elizabeth Grinspoon, Kamille Janess, Martin J Sliwinski, Ruth S Weinstock, Jasmeer P Chhatwal, Pia Kivisäkk, Laura Thi Germine, Naomi S Chaytor

{"title":"ATN blood biomarkers are related to digital cognitive assessment in type 1 diabetes.","authors":"Luciana Mascarenhas Fonseca, Michal Schnaider Beeri, Zoë W Hawks, Lanee Jung, Michael Cleveland, Nikki Delgado, Jane Bulger, Elizabeth Grinspoon, Kamille Janess, Martin J Sliwinski, Ruth S Weinstock, Jasmeer P Chhatwal, Pia Kivisäkk, Laura Thi Germine, Naomi S Chaytor","doi":"10.1002/dad2.70029","DOIUrl":null,"url":null,"abstract":"Introduction: Associations between amyloid-tau-neurodegeneration (ATN) plasma biomarkers and cognition have not been characterized in adults with type 1 diabetes (T1D).Methods: Using data from participants in the Glycemic Variability and Fluctuations in Cognitive Status in Adults with T1D (GluCog) study (N = 114), we evaluated associations between phosphorylated tau (pTau)181, pTau217, β-amyloid 42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) and self-administered digital cognitive tests, adjusting for age, sex, education, comorbidities (e.g., kidney disease), and glycemic indices.Results: Higher concentrations of pTau181 and GFAP were associated with slower responses on working memory tasks (pTau181: β = 0.261; p = 0.007; GFAP: β = 0.175, p = 0.036), and higher β-amyloid 42/40 ratio was associated with better vocabulary (β = 0.260, p = 0.009).Discussion: Digital cognitive performance was associated with several ATN plasma biomarkers in T1D adults. Prospective studies are needed to understand the utility of these biomarkers in T1D.Highlights: There is an increase in life expectancy for individuals with type 1 diabetes (T1D).Few studies investigate the relationship between T1D and neurodegeneration.We characterize the relation between ATN plasma biomarkers and cognitive function.Digital cognitive performance was associated with plasma biomarkers in T1D adults.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 4","pages":"e70029"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497176/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Associations between amyloid-tau-neurodegeneration (ATN) plasma biomarkers and cognition have not been characterized in adults with type 1 diabetes (T1D).

Methods: Using data from participants in the Glycemic Variability and Fluctuations in Cognitive Status in Adults with T1D (GluCog) study (N = 114), we evaluated associations between phosphorylated tau (pTau)181, pTau217, β-amyloid 42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) and self-administered digital cognitive tests, adjusting for age, sex, education, comorbidities (e.g., kidney disease), and glycemic indices.

Results: Higher concentrations of pTau181 and GFAP were associated with slower responses on working memory tasks (pTau181: β = 0.261; p = 0.007; GFAP: β = 0.175, p = 0.036), and higher β-amyloid 42/40 ratio was associated with better vocabulary (β = 0.260, p = 0.009).

Discussion: Digital cognitive performance was associated with several ATN plasma biomarkers in T1D adults. Prospective studies are needed to understand the utility of these biomarkers in T1D.

Highlights: There is an increase in life expectancy for individuals with type 1 diabetes (T1D).Few studies investigate the relationship between T1D and neurodegeneration.We characterize the relation between ATN plasma biomarkers and cognitive function.Digital cognitive performance was associated with plasma biomarkers in T1D adults.

查看原文本刊更多论文

ATN 血液生物标志物与 1 型糖尿病患者的数字认知评估有关。

引言淀粉样蛋白-Tau-神经变性（ATN）血浆生物标志物与 1 型糖尿病（T1D）成人认知能力之间的关系尚未定性：方法：我们利用 T1D 成人血糖变异和认知状态波动（GluCog）研究参与者（N = 114）的数据，评估了磷酸化 tau（pTau）181、pTau217、β-淀粉样蛋白 42/40 比值、胶质纤维酸性蛋白（GFAP）和神经丝光（NfL）与自测数字认知测试之间的关系，并对年龄、性别、教育程度、合并症（如肾病）和血糖变异进行了调整、结果发现，pTau18蛋白和神经丝光的浓度较高：结果：pTau181和GFAP浓度越高，工作记忆任务的反应越慢（pTau181：β = 0.261；p = 0.007；GFAP：β = 0.175，p = 0.036），β-淀粉样蛋白42/40比值越高，词汇量越大（β = 0.260，p = 0.009）：讨论：在T1D成人中，数字认知能力与几种ATN血浆生物标志物有关。需要进行前瞻性研究，以了解这些生物标志物在 T1D 中的作用：我们描述了ATN血浆生物标志物与认知功能之间的关系，T1D成人的数字认知能力与血浆生物标志物有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.